Pre-Conference Workshop: Enhanced Supportive Cancer Care  
8:30AM - 5:30PM

Join us for this one-day workshop which is for the full Cancer Care team - medical oncologists, nurses, general practitioners and other health professionals. Learn the best evidence based supportive care strategies for helping your patients through treatment and beyond. Understand what probiotics might be safe and optimise the gut for treatment, assist in treating chemotherapy induced diarrhoea, and optimising gut bacteria for enhanced response to immunotherapy (1); gain familiarity with what symptoms might be supported by non-pharmacological strategies such as acupuncture, oncology massage and mind-body practices; learn when and how to prescribe and administer medicinal cannabis; consider the practicalities and steps required to make enhanced supportive care part of your own clinical practice.

This conference acknowledges the sponsorship of

Pre-Conference Workshop: Nutrition & Cancer Masterclass for Nurses  
8:30AM - 5:30PM

This full day workshop is a masterclass in nutrition and cancer for nurses working with people affected by cancer. Participants will come away with an understanding of the pathophysiology of malnutrition, it’s consequences and practical implications; the impact of a cancer diagnosis on dietary intake and recommendations for practical management in the everyday clinical setting; knowledge of the current challenges in the nutritional management of cancer including the impact of celebrity nutrition messages via social media; and examples of successful, evidence-based multidisciplinary models of nutrition care. There will be opportunities to participate in case studies and discussions on topical issues. Participants can expect to finish the day feeling confident and well equipped with the knowledge to help facilitate optimal nutritional care in their clinical practice

This conference acknowledges the sponsorship of

Pre-Conference Workshop: Implementation and Dissemination of Evidence for Adoption and Application (IDEA)Concept Development Workshop  
12:30PM - 5:30PM

This interactive half day workshop will examine the fundamental concepts in implementation science to assist mid-career clinicians and researchers from diverse cancer disciplines to design and conduct research that is focused on implementation of evidence rather than efficacy alone. The workshop will be limited to 20 participants and will include large and small group discussions of research concepts brought by participants in order to refine the concepts and progress them to a full research protocol with support of the workshop faculty.

Applicants need to submit a one-page concept outline of their proposed implementation research/strategy and a brief CV (2-page maximum), and will be selected for participation based on the following criteria: scientific strength and future impact of the proposal, track record of the applicant. Please submit your application to cosa@cosa.org.au by 1 September 2017. The program will then be refined based on the application content to best meet the needs of the applicants.

This conference acknowledges the sponsorship of
Pre-Conference Workshop: Demystify and Personalise Clinical Trials Research
9:00AM - 5:00PM

Discover and extend your knowledge of the clinical trials research process. Together we will demystify statistical concepts in clinical trial design and reporting; review tools and techniques to improve the informed consent process for patients; and explore the key differences between RECIST v1.1, the conventional criteria for tumour measurement, and irRC, more recent criteria developed to assess tumour response to immunotherapeutic agents.
Statistical principles underpin critical appraisal of research; this session will concentrate on explaining concepts rather than formulae or calculation techniques. An overview of the National PICF Framework launched in 2016 and adopted in research active healthcare services and organisations will follow. Expanding upon this critical topic and led by a principal investigator/ facilitator, an interactive session on the clinical trial consent process will illustrate that informed consent is not a signature on a form but a communication process to achieve informed choice.
Join us for an effective learning experience to enhance understanding of the research process, improve communication skills and strengthen professional development.

This conference acknowledges the sponsorship of

Bellberry Limited
supporting research and ethics
Monday 13 November 2017

7:00 am - 8:15 am  Breakfast Session

Development of an enterprise-wide analytics strategy to support operational, clinical and research analytics by capitalizing on common data needs  
Meeting Room C4.3

Content: How we develop and use health data systems to support clinician decision making and research in cancer is a national priority. This workshop will explore this topic through a discussion with national and international leaders from both a technical, governance and clinical perspective. You will take away from the workshop an understanding of where we are at and how all the pieces of this complex jigsaw puzzle can fit together.

Speaker: Dana Rollison

The conference acknowledges the sponsorship of

Clinical Oncology Society of Australia

8:30 am - 9:00 am  Opening Ceremony

Chair: Phyllis Butow  
Welcome by COSA President  
Welcome to Country by local Indigenous group  
Official opening by His Excellency General The Honourable David Hurley AC DSC (Ret’d), Governor of New South Wales

9:00 am - 10:30 am  Plenary

Immunotherapy: Hype and hope?
Chair: Nick Pavlakis  
Darling Harbour Theatre

9:00 AM Jonathan Cebon
Overview and history of immunotherapy abs# 1

9:20 AM Matthew D. Hellmann
3-year overall survival for patients with advanced NSCLC treated with pembrolizumab abs# 2

9:40 AM Replacement TBC
Title TBC abs# 3

10:00 AM Panel Discussion

Morning Tea, Poster Viewing & Exhibition (see Monday poster listing at end of program)
10:30 am - 11:00 am  Hall 1
(Presenters to stand next to posters)

11:00 am - 12:30 pm  Concurrent Symposia

Interactions and integration
Chair: David Speakman  
Meeting Room C4.1

11:00 AM Nicole M Haynes
Radiation dose-fractionation influences the immune modulatory effects of radiotherapy and anti-cancer activity of checkpoint blockade therapy. *abs# 4*

11:15 AM Shankar Siva  
Current clinical trials investigating integration of immune therapy and radiotherapy: Focus on ablative radiotherapy combinations *abs# 5*

11:30 AM Mark Pinkham  
Integrating immunotherapy and stereotactic radiosurgery in the management of patients with brain metastases *abs# 6*

11:50 AM Brindha Shivalingam  
Cranial Radiosurgery and immune therapy. Should we be concerned re toxicity? *abs# 7*

12:10 PM Mark Shackleton  
Immunosuppression and immunotherapy: Who to rob - Peter or Paul? *abs# 8*

**Data leadership - inspiring clinicians to improve cancer services**  
Chair: David Thiele  
Meeting Room C4.2

11:00 AM Mark Smithers  
Outcomes of complex cancer surgery in Queensland *abs# 9*

11:15 AM Colin Furnival  
Variations in breast cancer management: Identifying outliers and how to address them *abs# 10*

11:30 AM Nicholas Lutton  
The value of a population-wide audit: Queensland Colorectal Cancer Audit 2012 and 2014 *abs# 11*

11:45 AM Kwun Fong  
Population-wide treatment data informs clinical management of lung cancer in Queensland *abs# 12*

**Best of the Best Orals - Education**  
Chair: Ian Olver  
Meeting Room C4.3

Discussant: Nicole Kiss

11:00 AM Natalie Bradford  
Education needs of health professionals caring for adolescents and young adults with cancer *abs# 13*

11:15 AM Ilona Juraskova  
A randomised controlled trial of a treatment decision-aid for asymptomatic women with rising CA-125 after successful first line therapy for ovarian cancer *abs# 14*

11:30 AM Amber Kelaart  
Implementing Pathways for Cancer Early Detection (I-PACED): Identifying systems level issues in primary care *abs# 15*

11:45 AM Bettina Meiser  
Evaluation of an online communication skills training programme for oncology health care professionals working with culturally and linguistically diverse patients *abs# 16*

12:00 PM Joanne Shaw  
Identifying and responding to anxiety and depression in adult cancer patients: Pilot testing of an on-line communication skills education program targeting challenging conversations for oncology health professionals *abs# 17*

Session sponsored by
You pay for what you get? Cost and value in cancer
Chair: Deme Karikios  Meeting Room C4.4
11:00 AM Nicola Lawrence
Assessing the benefits of anticancer drugs: update on the ASCO and ESMO value framework abs# 18
11:15 AM Richard Vines
Public perception of value with immunotherapy abs# 19
11:30 AM Adam Elshaug
Disinvestment from low-value cancer care: Part of the next quality frontier abs# 20
11:50 AM Richard De Abreu Lourenco
Assessing the cost-effectiveness of immunotherapy: Do modern drugs need modern methods? abs# 21

Patient Safety: Deviation or deviant (human error, system or cultural failures)
Chair: Gabrielle Prest  Meeting Room C4.5
11:00 AM Dorothy M Keefe
To err is human... prescribing errors in cancer treatment abs# 22
11:15 AM Robert Thomas
A Sydney Hospital’s experience in response to a Chemotherapy dosage controversy abs# 23
11:30 AM Matthew J Links
Peer Review - improving performance in practice. abs# 24
11:40 AM Maree Bransdon & Liz Kenny
Standards, Governance and ICT: the holy trinity for systemic therapies? abs# 25
11:50 AM Anthony Joshua
Making Medicine Safe – Lessons from Boeing, Hopkins & Tom Hanks abs# 26
12:00 PM Panel Discussion

The tide has turned: Psychosocial initiatives within cancer services that support patient-centred care
Chair: Afaf Girgis  Hall 1 - Theatrette
11:00 AM Brian Kelly
Integrating psychosocial care into cancer services: The path from evidence to implementation abs# 27
11:25 AM Afaf Girgis
PROMPT-Care: A fully integrated eHealth system to support patient-centred cancer care and self-management abs# 28
11:50 AM Heather Shepherd
Making screening, assessment, referral and management of anxiety and depression in cancer care a reality: developing a system addressing barriers and facilitators to support sustainable implementation abs# 29

<table>
<thead>
<tr>
<th>Lunch &amp; Exhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 pm - 1:30 pm</td>
</tr>
<tr>
<td>COSA Nutrition Group Meeting</td>
</tr>
<tr>
<td>COSA Cancer Pharmacists Group Meeting</td>
</tr>
<tr>
<td>COSA Regional and Rural Group Meeting</td>
</tr>
<tr>
<td>COSA Psycho-oncology Group Meeting</td>
</tr>
<tr>
<td>COSA Survivorship Group Meeting</td>
</tr>
<tr>
<td>Meeting Room C4.1</td>
</tr>
<tr>
<td>Meeting Room C4.2</td>
</tr>
<tr>
<td>Meeting Room C4.3</td>
</tr>
<tr>
<td>Meeting Room C4.4</td>
</tr>
<tr>
<td>Meeting Room C4.5</td>
</tr>
<tr>
<td>Hall 1</td>
</tr>
<tr>
<td>1:30 pm - 3:00 pm</td>
</tr>
<tr>
<td>Plenary</td>
</tr>
</tbody>
</table>
Quality - proactive or reactive?
Chair: Bogda Koczwara 
Darling Harbour Theatre
1:30 PM Clifford Hughes
Quality: Proactive or Reactive? - An Australian Perspective abs# 30
1:50 PM Monika Krzyzanowska
Evolution of Quality Based Medicine: How do we get from reactive to proactive? abs# 31
2:10 PM Carrie Marr
Creating learning systems for quality and safety in cancer care abs# 32
2:30 PM Grant Mundell
Quality - Proactive or Reactive (A Consumer Perspective) abs# 33
2:50 PM Panel Discussion

Afternoon Tea, Poster Viewing & Exhibition (see Monday poster listing at end of program)
3:00 pm - 4:00 pm  
Poster Session 1
3:00 pm - 4:00 pm  
(Presenters to stand next to posters)

Best of Best Poster discussion - Translational Research
3:20 pm - 3:45 pm  
Chair: Phyllis Butow
Discussant: TBC
3:20 PM Nathan Dunn
Systemic therapy as treatment for Queensland colorectal cancer patients abs# 132
3:25 PM Jean-Francois Laes
Combining analysis of solid and liquid biopsy: insights into tumor heterogeneity abs# 133
3:30 PM Visalini Nair-Shalliker
The associations between variants in pigmentary genes, and serum prostate specific antigen levels: Results from the Concord Health and Ageing in Men Project. abs# 134
3:35 PM Samad Raza
Can ERBB4 induce nuclear YAP in High Grade Glioma? abs# 135
Session sponsored by

Best of Best Poster discussion - Clinical Research and Supportive Care
3:20 pm - 3:40 pm  
Chair: Suzanne Grant
Discussant: Haryana Dhillon 3:20 PM Elise J Devlin
Just as I expected: The impact of pre-treatment response expectancies of radiotherapy toxicities abs# 136
3:25 PM Paul Mainwaring
Overall survival (OS) in METEOR, a randomised phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma (RCC) abs# 137
3:30 PM Kate J Wilkinson
Application of clinical guidelines in the management of small cell lung cancer abs# 138

Session sponsored by

Innovative ways of delivering care
Chair: Laura Kirsten
C4.14:00 PM Danette H Langbecker
Telehealth for cancer care: challenges and opportunities abs# 34

4:20 PM Afaf Girgis
Does it matter who addresses the psychosocial issues as long as someone does? abs# 35

4:40 PM Joanne Shaw
Integration of online therapy for anxiety and depression into routine cancer care abs# 36

5:00 PM Ilona Juraskova
Facilitating effective family involvement in cancer care: Clinical practice guidelines and online clinician training abs# 37

Best of the Best Orals - Basic Science and Translational Research
Chair: Nikolajs Zeps
Discussant: Rik Thompson
Meeting Room C4.2

4:00 PM Nicola S Meagher
Mucinous ovarian cancers of uncertain primary (MO-CUP) - does the site of origin really matter? abs# 38

4:15 PM Tim J Miller
The Cancer Stem-Like Cell Marker SOX2 is Prognostic and May Predict Response to Chemotherapy in Colon Cancer abs# 39

4:30 PM Kate R Secombe
Budesonide reduces neratinib-induced gastrointestinal injury and diarrhoea in rats abs# 40

4:45 PM Charlie, Seong Beom Ahn
Detection of Plasma Colorectal Cancer Prognostic Biomarkers abs# 41

5:00 PM Favil Singh
Supervised on-site exercise during acute radiation treatment: effect on muscle strength, physical function and body composition. abs# 42

Session sponsored by

Best of the Best Orals - Clinical Research
Chair: Bogda Koczwara
Discussant: Monika Krzyzanowska 4:00 PM Michael Back
Meeting Room C4.3
Avoiding whole brain radiation therapy for brain metastases in the era of targeted therapies and immunotherapy. *abs# 43*

4:15 PM **Rina Hui**
Progression after the next line of therapy (PFS2) and updated OS among patients with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024. *abs# 44*

4:30 PM **Thomas John**
CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3) *abs# 45*

4:45 PM **Gayle Jones**
Priority-driven Collaborative Cancer Research Scheme (PdCCRS) – 10 year look back *abs# 46*

5:00 PM **Christopher B Nahm**
Patterns of multiple immunohistochemical biomarker expression predict survival after resection in pancreatic ductal adenocarcinoma: a retrospective cohort study and two-step cluster analysis. *abs# 48*

Session sponsored by

**Managing toxicity in the era of immuno-oncology: A multidisciplinary view**
Chair: Anthony Joshua  
Meeting Room C4.4

4:00 PM **Stephen J Tattersall**
An Overview of the Management of Gastrointestinal Toxicities from Checkpoint Inhibitors  *abs# 49*

4:20 PM **Venessa Tsang**
An Endocrinologist’s View: Diagnosis and Management of Immunotherapy Related Endocrinopathies *abs# 50*

4:40 PM **Donna Milne**
Managing patients with immune-related side effects – The nurse’s role *abs# 51*

5:00 PM **Christine Carrington**
The role of the pharmacist in the management of immune-related toxicities *abs# 52*

5:20 PM Panel Discussion

**Using data to drive change**
Chair: Geoff Delaney  
Meeting Room C4.5

4:00 PM **Tim Shaw**
Using data to drive change in breast cancer care *abs# 53*

4:15 PM **Richard Khor**
Implementing Cerner Oncology in a metropolitan cancer service: the process and lessons learnt *abs# 54*

4:30 PM **Dana Rollison**
An enterprise-wide analytics strategy to drive change in cancer care delivery and research *abs# 55*

4:45 PM **David Currow**
Cancer Institute NSW’s vision for integrating data for cancer research: the role of registries. *abs# 56*

5:00 PM **Emily Stone**
Just where is data that is relevant to clinical teams hidden? Building a useful map *abs# 57*

5:15 PM Panel Discussion
Welcome Function
5:30 pm - 7:00 pm
Hall 1
2nd line NSCLC - how new therapies are changing the Australian treatment landscape  

Meeting Room C4.1

Content: In 2017 the Australian treatment landscape in 2nd line non-small cell lung cancer (NSCLC) continues to rapidly change and evolve. New therapies in both non-mutation and mutation driven disease have recently become available allowing for greater choice in the treatment of this devastating disease. The question now has become, how do these therapies differ and which of these differentiating factors are important to both clinicians and patients. Lastly, in this era of changing medicine with different mode of actions and corresponding side effect profiles, who else needs to be involved to ensure optimal care of 2nd line NSCLC? In this Roche-sponsored breakfast symposium Dr Adnan Nagrial will discuss “Treatment choices and managing patients with non-mutation 2nd line NSCLC” and Dr Steven Kao will discuss “2nd line ALK and NSCLC - approach to targeted therapies”. Prof Stephen Clarke will chair this session which aims to give Australian oncologists practical guidance on differentiating/choosing therapies and managing patients the rapidly evolving treatment landscape, particularly focusing on recent data and new therapies available to 2nd line NSCLC patients.

Chair: Prof Stephen Clarke

Speakers: Adnan Nagrial and Steven Kao

The conference acknowledges the sponsorship of

Cancer Pain Symposium  

Meeting Room C4.3

Content: This symposium will be an update on the current management of cancer pain, exploring the current basis of treatment and its limitations and discussing alternative management options in common practice in the U.S.A and Europe. The first session by Professor Paul Glare will discuss Opiate medication, its development as the mainstay of cancer pain management and the W.H.O model. Despite this development, opioids have limited efficacy and the model of cancer pain management has not changed despite the enormous progress seen in oncology treatment. Furthermore, with oncological advances the profile of the patient during or post cancer treatment specifically has changed drastically in the lifespan of the W.H.O model. Additionally, the landscape of opiate misuse has changed drastically with Australia experiencing an “opiod epidemic”. Chronic non-cancer pain management has altered in this time to carefully protocolised opioid therapy. Cancer pain management is still considered as a separate entity to non-cancer pain management, however, considerable overlap exists with the oncology patient experiencing multiple non oncological morbidities. Many further similarities exist between these populations and therefore chronic non-cancer pain management can be adapted to provide multidisciplinary, efficacious and non opioid based pain solutions in patients with cancer. The second session from Dr Tim Hucker will discuss non opioid medication and interventional options for cancer pain management. euphoretic pain is prevalent in cancer, either from the cancer itself or its treatment and throughout the cancer journey. Even in survivorship, neuropathic pain is common and persistent. The limitation of efficacy in opiate management of neuropathic pain will be highlighted. Despite being part of cancer pain management guidelines and contrary to other countries, interventional pain options are infrequently considered. There are a wide variety of pain syndromes in the cancer patient and interventional options exist in many situations. The careful application of interventional techniques in this population will aid efficacy and also assist in limiting opiate related side effects and wider opiate burden.

Chair: Tim Hucker

Speakers: Tim Hucker and Paul Glare
The conference acknowledges the sponsorship of

Medtronic

<table>
<thead>
<tr>
<th>9:00 am - 10:30 am</th>
<th>Plenary</th>
</tr>
</thead>
</table>

**Patient selection & biomarkers**
Chair: Alexander Menzies  
Darling Harbour Theatre

9:00 AM **Matthew D. Hellmann**  
Lung cancer patient selection (clinical biomarkers) abs# 58

9:20 AM **Georgina Long**  
Predicating response and resistance in drug therapy for advanced melanoma abs# 59

9:40 AM **Richard Scolyer**  
Predictive markers of response and resistance to immunotherapies abs# 60

10:00 AM **Alexander Menzies**  
Treating non-trial populations abs# 61

10:20 AM Panel Discussion

---

<table>
<thead>
<tr>
<th>Morning Tea, Poster Viewing &amp; Exhibition (see Tuesday poster listing at end of program)</th>
<th>Hall 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 am - 11:00 am</td>
<td>(Presenters to stand next to posters)</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>11:00 am - 12:30 pm</th>
<th>Concurrent Symposia</th>
</tr>
</thead>
</table>

**Medicine matters**
Chair: Gail Rowan  
Meeting Room C4.1

11:00 AM **Matteo Carlino**  
Beyond PD1’s emerging therapies abs# 62

11:20 AM **Craig Gedye**  
New indications in GU cancers abs# 63

11:40 AM **Ben Solomon**  
Update on current lung cancer trials abs# 64

12:00 PM **Graham Rivers**  
Compassionate Access and Cost Share Programs: The Pharmacy Perspective abs# 65

**Best of the Best Orals - Health Services**
Chair: Dan McKavanagh  
Discussant: Claire Vajdic  
Meeting Room C4.2

11:00 AM **Christie Allan**  
Clinical Trial Activity in Victoria: Cancer Trials Management Scheme Data, 2009 to 2015. abs# 66

11:15 AM **Jon Emery**  
The Improving Rural Cancer Outcomes (IRCO) Trial: a factorial cluster-randomised controlled trial of a complex intervention to reduce time to diagnosis in rural cancer patients in Western Australia. abs# 67

11:30 AM **Jolyn Hersch**  
Informing women about overdetection in breast cancer screening: Randomised controlled trial with 2-year follow-up abs# 68
11:45 AM Paul Mitchell
Hospital lung surgery volume and patient outcomes in Victoria abs# 69

12:00 PM Haitham Tuffaha
Improving patient access to novel cancer drugs in Australia: are we there yet? abs# 70

12:15 PM Belinda Yeo
Testing wisely: when is both HER2 immunohistochemistry and in-situ hybridisation really necessary? abs# 71

Session sponsored by

Best of the Best Orals - Supportive Care
Chair: Alan Coates
Discussant: TBC
Meeting Room C4.3

11:00 AM Prue Cormie
One size doesn’t fit all: Responders and non-responders to exercise interventions for cancer patients and survivors abs# 72

11:15 AM Haryana M Dhillon
Is it feasible to delivery an online psycho-sexual intervention (Rekindle) to Australian cancer survivors and their partners: a randomised phase II feasibility study abs# 73

11:30 AM David Mizrahi
Do childhood cancer survivors achieve recommended physical activity levels? A report from the ANZCHOG Survivorship Study abs# 74

11:45 AM Martin Tattersall
A randomized controlled trial of an advance care planning intervention for patients with incurable cancer abs# 75

12:00 PM Bianca Tomalin
Financial toxicity, employment and quality of life of cancer survivors. A secondary analysis of the PROFILES registry. abs# 76

Session sponsored by

How to deliver immunotherapy in your clinical environment
Chair: Alexander Menzies
Meeting Room C4.4

11:00 AM Donna Milne
Nurses role in the assessment and management of patients on I-O drugs abs# 77

11:15 AM Rob Zielinski
Models of Care for Immunotherapy Patients abs# 78

11:30 AM Christopher Steer
Safe delivery of immunotherapy: A private cancer physician’s perspective abs# 79

11:45 AM Katherine Clark
Models of care for immunotherapy patients: Palliative care perspective abs# 80
12:00 PM Panel Discussion

**Translating evidence into practice: Why does it take 20 years?**
Chair: Tim Shaw
11:00 AM Nicole Rankin
C4.5  Systematic approaches to reduce time to implementation  abs# 81

11:15 AM Dana Rollison
Moffitt clinical pathways: translating evidence into standardized practice  abs# 82

11:30 AM Christine Paul
The role of inspiration, perspiration and evidence in research translation  abs# 83

11:45 AM Alexandra Barratt
A framework for de-intensification of cancer screening programs  abs# 84

12:00 PM Panel Discussion

---

**Lunch & Exhibition**
12:30 pm - 1:30 pm  Hall 1
COSA AGM  Meeting Room C4.5

---

**MDT panel discussion**
Chair: Nick Pavlakis  Darling Harbour Theatre
Co-Chair: Alexander Menzies

This sessions follows a highly successful format used at previous meetings. It is designed to provide a forum for discussion of the complex issues which arise in the care of patients undergoing immunotherapy treatment. The facilitators will present a series of challenging clinical cases and engage members of the multidisciplinary panel in discussion. There will also be opportunities for members of the audience to contribute to the discussion. Panellists will include a medical oncologist, radiation oncologist, surgeon, palliative care physician, nurse, psycho-oncologist and consumer.

---

**Afternoon Tea, Poster Viewing & Exhibition** (see Tuesdays poster listing at end of program)
3:00 pm - 4:00 pm  Hall 1  Poster

**Session 2**
3:00 pm - 4:00 pm
(Presenters to stand next to posters)  Hall 1

---

**Best of Best Poster discussion - Improving Cancer Health Services**
3:20 pm – 3:45 pm  Hall 1 - Theatrette 1
Chair: Patsy Yates
Discussant: Mei Krishnasamy

3:20 PM Olayinka O Akinsanmi
Tools at hand-Educational standardisation  abs# 280

3:25 PM Vikneswary Batumalai
Impact of radiotherapy underutilisation measured by survival shortfall, years of potential life lost and disability-adjusted life years lost  abs# 281

3:30 PM Jacqui Frowen
Introduction of a speech pathology assistant role for swallow screening in a head and neck radiotherapy clinic  abs# 282
3:35 PM Jenelle Loeliger
Reducing the cancer malnutrition burden: highlights of state-wide collaborations in Victorian health services
abs# 283

3:40 PM Hanna E Tervonen
Risk of emergency hospitalisation following adjuvant chemotherapy for early breast cancer in NSW abs# 284

Session sponsored by

Best of Best Poster discussion - Quality and Safety in Cancer Care
3:20 pm – 3:45 pm

Chair: Michael Powell
Discussant: Deirdre D'Souza
3:20 PM Natalie Bradford
Improving the clinical practice for fertility preservation abs# 285

3:25 PM Abhijit Pal
Staging scans (SS) in pre-operative, asymptomatic, stage I/II early breast cancer (EBC) patients (pts) at Bankstown-Lidcombe Hospital abs# 286

3:30 PM Janelle Penno
Improving medication labelling – patients driving their information abs# 287

3:35 PM Graham Pitson
Using data to drive change. Evaluation of Cancer Outcomes Barwon South West (ECOBSW) Registry abs# 288

3:40 PM Carmel Vermeltfoort
Assessing ovarian cancer care in Victoria against the optimal care pathway abs# 289

Session sponsored by

Oral cancer treatment
Chair: Vicki Wilmott

Meeting Room C4.1

4:00 PM Monika Krzyzanowska
Oral cancer treatment: Making it safe abs# 85

4:15 PM Howard Gurney
Dosing considerations with oral cancer treatments abs# 86

4:30 PM Gail Rowan
Oral cancer treatments: Drug interactions & other challenges abs# 87

4:45 PM Polly H Dufton
Rapid-assessment nurse clinic: exploring reasons for ED presentation during oral cancer treatment abs# 88

5:00 PM Aisling Kelly
Closing the gap: Educating community pharmacists on oral antineoplastic treatments abs# 89
Best of the Best Orals - Epidemiology
Chair: Paul Katris
C4.2 Discussant: Prue Cormie 4:00 PM Annika Antonsson
Sexual behaviour, HPV status and p16 expression in oropharyngeal and oral cavity squamous cell carcinoma patients abs# 90

4:15 PM Benjamin Daniels
Patterns of care and outcomes for long-term survivors with HER2-positive metastatic breast cancer (HER2+MBC) starting trastuzumab: an Australian whole-of-population cohort study abs# 91

4:30 PM Abbey Diaz
Higher comorbidity burden does not explain lower survival for Indigenous Australian women with cervical cancer abs# 92

4:45 PM Gemma Jacklyn
Trends in stage-specific breast cancer incidence in New South Wales, Australia: insights into the effects of 25 years of screening mammography abs# 93

5:00 PM Maarit A Laaksonen
Premenopausal and postmenopausal breast cancer burden attributable to health behaviours and hormonal factors abs# 94

Session sponsored by

Best of the Best Orals - Quality and Safety
Chair: Tim Shaw
C4.3 Discussant: Dana Rollison

4:00 PM Susan Hanson
Enhancing regional cancer services across Australia to improve outcomes for rural and regional cancer patients abs# 95

4:15 PM Colin Hornby
Improving radiotherapy quality through collaboration abs# 96

4:30 PM Graham Pitson
Population-Based Analysis of Radiotherapy and Chemotherapy Treatment in the Last Month of Life abs# 97

4:45 PM Ursula M Sansom-Daly
Doing better at ‘Difficult Discussions’: Australian Oncology Professionals’ perspectives on End-of-Life communication with adolescents and young adults with cancer abs# 98

5:00 PM Ben Smith
Cancer research participation by culturally and linguistically diverse (CALD) patients in South Western Sydney from 2006 - 2016: A retrospective analysis abs# 99

Session sponsored by
Treatment adherence and compliance
Chair: Joanne Shaw  
Meeting Room C4.4
4:00 PM **Kim Hobbs**
Money matters: the effects of financial toxicity on treatment compliance *abs# 100*

4:20 PM **Tish Lancaster**
Social determinants of treatment adherence. *abs# 101*

4:40 PM **Jane Turner**
Even checked baggage flies with us: We can’t escape our past experiences when confronted by cancer *abs# 102*

5:00 PM **Maree Grier**
“Like approaching the edge of a cliff” ... How mood, fear, and beliefs affect adherence *abs# 103*

Living well with immunotherapies
Chair: Jane Turner  
Meeting Room C4.5
4:00 PM **Michael Marthick**
Exercise and Immunotherapy *abs# 104*

4:15 PM **Luis Vitetta**
The intestinal microbiome, chemotherapy and adjuvant treatments with probiotics. *abs# 105*

4:35 PM **Penelope Sanderson**
Complementary and integrative therapies *abs# 106*

4:55 PM **Judith Lacey**
Supportive and palliative care *abs# 107*

5:15 PM **Karen van Gorp**
Living well with immunotherapies - the patient perspective *abs# 108*

COSA Exercise and Cancer Group Meeting
5:30 pm - 6:30 pm  
Meeting Room C4.2

Conference Dinner
7:00 pm - 11:30 pm  
Grand Ballroom B1

Including the Tom Reeve Oration – Emeritus Professor William McCarthy AM
Moving Mountains in NSCLC - The new era of IO for 1L lung cancer treatment

**Meeting Room C4.1**

**Content:** Please join us for a scientific update on new treatment paradigms in 1L lung cancer and how these will impact clinical outcomes, with a specific focus on the role of immunotherapy.

**Chair:** TBC

**Speaker:** TBC

The conference acknowledges the sponsorship of

[MSD]

Scalp Cooling - Meeting the growing demand

**Meeting Room C4.3**

**Content:** TBC

**Chair:** Dr Michelle White, Oncologist, Monash Health and Cabrini

**Speaker:** TBC

The conference acknowledges the sponsorship of

[Regional Health Care Group]

Exploring the forgotten genome of cancer research

**Meeting Room C4.4**

**Content:** Sarcomas are a rare, phenotypically heterogeneous family of cancers that disproportionately affects the young. Although the study of rare sarcoma families has contributed richly to cancer biology, the genetic architecture of cancer risk has not previously been studied in the sarcoma population. Professor Thomas will discuss the International Sarcoma Kindred Study (ISKS) and how a unique genetic panel of genes associated with cancer risk has been developed. The frequency of potentially actionable monogenic and polygenic germline variants in the ISKS cohort warrants attention as personalized medicine evolves, with special relevance to other young-onset cancers.

**Chair:** Kahill Lawless

**Speaker:** David Thomas, Garvan Institute of Medical Research,

The conference acknowledges the sponsorship of

[illumina]

Becoming a Pro with PRO

**Meeting Room C4.5**

**Content:** There is growing evidence that incorporating patient reported outcomes (PROs) into the care of patients with cancer is beneficial to patient care and health system planning. However, implementing PROs into routine practice is a complex undertaking that requires appropriate planning and support. In this session we will briefly review some of the history and evidence for use of PROs in oncology and spend the majority of
our time discussing implementation issues drawing on existing experiences across healthcare systems and discuss approaches for successful implementation using a case-based approach.

**Chair:** Afaf Girgis  
**Speaker:** Monika Krzyzanowska

The conference acknowledges the sponsorship of

![Clinical Oncology Society of Australia](image)

### 9:00 am - 10:30 am  
**Plenary**

**Uncertainty in the age of immunotherapy: Surviving against the odds**  
Chair: Jane Turner  
Darling Harbour Theatre

9:00 AM **Catriona McNeil**  
How long will this go on? Decisions about treatment duration and stopping. *abs# 109*

9:15 AM **Geoffrey Mitchell**  
Uncertainty in immunotherapy raises the question: what is the GP role in primary cancer treatment? *abs# 110*

9:30 AM **TBC**  
Speaker TBC (Caregiver)

9:45 AM **Mei Krishnasamy**  
When am I a survivor: changing perspectives on metastatic cancer and its impact on cancer nursing *abs# 112*

10:00 AM **Haryana Dhillon**  
**Title TBC abs# 113**

10:15 AM Panel discussion

### Morning Tea & Exhibition  
10:30am - 11:00am  
**Hall 1**

### 11:00 am – 12:30 pm  
**Concurrent Symposia**

**Cancer genetics in the new era**  
Chair: Kathy Wu  
Meeting Room C4.1

11:00 AM **Aung Win**  
Colorectal cancer genetics and precision medicine in the new era *abs# 114*

11:20 AM **Kathy Tucker**  
Utility of panel testing in familial cancer *abs# 115*

11:40 AM **Margaret Lee**  
Immunotherapy in dMMR and Lynch syndrome Gastrointestinal tumours *abs# 116*

12:00 PM **Natalie Taylor**  
Translating cancer genetics evidence into practice: impact on patients and practitioners *abs# 117*
Reforming cancer care
Chair: Patsy Yates
Meeting Room C4.3

11:00 AM Kathryn Whitfield
The role of optimal care pathways in achieving system reform  abs# 118

11:20 AM Mei Krishnasamy
Implementing optimal care pathways: Using data to drive improvements   abs# 119

11:40 AM Jon D Emery
Primary health care reform – implications for cancer care  abs# 120

12:00 PM Anne M Develin
Innovations in community pharmacy: implications for cancer care  abs# 121

12:20 PM Panel Discussion

Non immune cancers: Cold tumours and how to make them hot!
Chair: Matt Carlino
Meeting Room C4.4

11:00 AM Tobias Bald
Immunotherapy vol.2: Desperately looking for hot tumors  abs# 122

11:25 AM Jonathan Cebon
Some like it hot!  abs# 123

11:50 AM Elizabeth Ahern
Targeting RANK Ligand Pathways in Combination Immunotherapy  abs# 124

Guidelines - friend or foe?
Chair: Tim Shaw
Meeting Room C4.5

11:00 AM Jutta Thwaites
Digital Guidelines - an International Perspective  abs# 125

11:15 AM Davina Ghersi
Maintaining the Standard of Guidelines  abs# 126

11:30 AM Phyllis Butow
Challenges of writing new guidelines  abs# 127

11:45 AM Christine Carrington
Chemotherapy Guidelines and Controversy. The safe delivery of cancer therapy.   abs# 128

12:00 PM Ian N Olver
Using Education to Disseminate and implement Guidelines  abs# 129

12:45 PM Panel Discussion

Lunch & Exhibition
12:30 pm - 1:30 pm Hall 1

COSA Presidential Lecture
1:30 pm - 2:30 pm Darling Harbour Theatre
Chair: Phyllis Butow
Speaker: Richard De Crespigny

Hot Topic Discussion: Cancer services are leading the way in health services reform
2:30 pm - 3:30 pm Darling Harbour Theatre
Moderator: Adam Spencer
Panel: TBC

Conference Close
3:30 pm - 3:45 pm
Darling Harbour Theatre